Spero Therapeutics, Inc. (SPRO) Q1 2026 Earnings
Spero Therapeutics, Inc. reported Q1 2026 revenue of $258.0K (-95.6% YoY). Diluted EPS came in at $-0.13 (+48.0% YoY), beat the $-0.18 consensus by $0.05.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Spero Therapeutics, Inc.'s Q1 2026 earnings report.
Spero Therapeutics, Inc. (SPRO) reported Q1 2026 earnings on May 13, 2026 after market close.
Spero Therapeutics, Inc. reported revenue of $258.0K and diluted EPS of $-0.13 for Q1 2026.
Revenue beat the consensus estimate of $258.0K by -. EPS beat the consensus estimate of $-0.18 by $0.05.
Compared to the same quarter a year prior, revenue declined 95.6% from $5.9M a year earlier and diluted EPS grew 48.0% from $-0.25.
You can read the 8-K earnings release (0001193125-26-221567) and the 10-Q periodic report (0001193125-26-221591) directly on SEC EDGAR. The filing index links above go to sec.gov.